关键词：眼睛疾病；视网膜；糖尿病；影响；视网膜
摘 要：DR is defined as an eye disorder that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye that acts as a film for the formation of an image. Longterm diabetes affects the retina as a high blood glucose level can damage the tiny blood vessels in the retina. DR is broadly classified as non-proliferative DR and proliferative DR. The treatment for DR is dependent on the stage of the disease and is directed at trying to slow or stop the progression of the disease. At present, three types of treatment exist for DR, namely: laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Prevalence of DR

08.1.1 America

08.1.2 Europe

08.1.3 APAC Region

09. Geographical Segmentation

09.1 Diabetic Retinopathy Market in the Americas

09.1.1 Market Size and Forecast

09.2 Diabetic Retinopathy Market in the EMEA Region

09.2.1 Market Size and Forecast

09.3 Diabetic Retinopathy Market in the APAC Region

09.3.1 Market Size and Forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

17.1 Competitive Scenario

17.1.1 Key News

17.1.2 Mergers and Acquisitions

17.2 Market Share Analysis 2013

17.3 Other Prominent Vendors

17.4 Future Players Expected To Tap the DR Market

18. Key Vendor Analysis

18.1 Bayer AG

18.1.1 Key Facts

18.1.2 Business Overview

18.1.3 Business Segmentation

18.1.4 Business Segmentation by Revenue 2012 and 2013

18.1.5 Sales by Geography

18.1.6 Business Strategy

18.1.7 Key Information

18.1.8 SWOT Analysis

18.1.9 Strengths

18.1.10 Weaknesses

18.1.11 Opportunities

18.1.12 Threats

18.2 F. Hoffmann-La Roche Ltd.

18.2.1 Key Facts

18.2.2 Business Overview

18.2.3 Business Segmentation

18.2.4 Business Segmentation by Revenue 2012 and 2013

18.2.5 Sales by Geography

18.2.6 Business Strategy

18.2.7 Key Information

18.2.8 SWOT Analysis

18.2.9 Strengths

18.2.10 Weaknesses

18.2.11 Opportunities

18.2.12 Threats

18.3 Novartis AG

18.3.1 Key Facts

18.3.2 Business Overview

18.3.3 Business Segmentation by Revenue 2013

18.3.4 Business Segmentation by Revenue 2012 and 2013

18.3.5 Sales by Geography

18.3.6 Business Strategy

18.3.7 Key Developments

18.3.8 SWOT Analysis

18.3.9 Strengths

18.3.10 Weaknesses

18.3.11 Opportunities

18.3.12 Threats

18.4 Pfizer Inc.

18.4.1 Key Facts

18.4.2 Business Overview

18.4.3 Business Segmentation by Revenue 2013

18.4.4 Business Segmentation by Revenue 2012 and 2013

18.4.5 Sales by Geography

18.4.6 Business Strategy

18.4.7 Key Developments

18.4.8 SWOT Analysis

18.4.9 Strengths

18.4.10 Weaknesses

18.4.11 Opportunities

18.4.12 Threats

18.5 Regeneron Pharmaceuticals Inc.

18.5.1 Key Facts

18.5.2 Business Overview

18.5.3 Product Segmentation by Revenue 2013

18.5.4 Business Strategy

18.5.5 Key Information

18.5.6 SWOT Analysis

18.5.7 Strengths

18.5.8 Weaknesses

18.5.9 Opportunities

18.5.10 Threats

18.6 Valeant Pharmaceuticals International Inc.

18.6.1 Key Facts

18.6.2 Business Overview

18.6.3 Business Segmentation by Revenue 2013

18.6.4 Business Segmentation by Revenue 2012 and 2013

18.6.5 Sales by Geography

18.6.6 Business Strategy

18.6.7 Key Developments

18.6.8 SWOT Analysis

18.6.9 Strengths

18.6.10 Weaknesses

18.6.11 Opportunities

18.6.12 Threats

19. Other Reports in this Series